Vanda Pharmaceuticals, Inc. (VNDA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Phibro Animal Health Corp.

Soleno Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Ovid Therapeutics, Inc.

Vanda Pharmaceuticals, Inc.

Compass Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

Atea Pharmaceuticals, Inc.

Inozyme Pharma, Inc.

Third Harmonic Bio, Inc.

Acumen Pharmaceuticals, Inc.

Why is Vanda Pharmaceuticals, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of -2.73% over the last 5 years

The company has declared negative results for the last 8 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at USD -109.45 MM
ROCE(HY) Lowest at -50.93%
RAW MATERIAL COST(Y) Grown by 5.71% (YoY)

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 46.75%, its profits have fallen by -1066.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vanda Pharmaceuticals, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Vanda Pharmaceuticals, Inc.

46.75%

0.22

76.99%

S&P 500

16.12%

0.84

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-2.73%

EBIT Growth (5y)

-240.88%

EBIT to Interest (avg)

-3.96

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.66

Sales to Capital Employed (avg)

0.40

Tax Ratio

20.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

92.33%

ROCE (avg)

23.96%

ROE (avg)

2.66%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.59

EV to EBIT

-1.74

EV to EBITDA

-1.88

EV to Capital Employed

3.81

EV to Sales

1.21

PEG Ratio

Dividend Yield

ROCE (Latest)

-219.75%

ROE (Latest)

-67.38%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -76.82 %

NET SALES(Q)

Highest at USD 57.22 MM

-25What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -109.45 MM

ROCE(HY)

Lowest at -50.93%

RAW MATERIAL COST(Y)

Grown by 5.71% (YoY

CASH AND EQV(HY)

Lowest at USD 557.7 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.25 times

PRE-TAX PROFIT(Q)

Lowest at USD -38 MM

NET PROFIT(Q)

Lowest at USD -141.19 MM

EPS(Q)

Lowest at USD -2.39

Here's what is working for Vanda Pharmaceuticals, Inc.

Net Sales

Highest at USD 57.22 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Debt-Equity Ratio

Lowest at -76.82 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Depreciation

Highest at USD 5.86 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation

At USD 5.86 MM has Grown at 185.58%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for Vanda Pharmaceuticals, Inc.

Pre-Tax Profit

At USD -38 MM has Fallen at -41.88%

over average net sales of the previous four periods of USD -26.79 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -141.19 MM has Fallen at -570.73%

over average net sales of the previous four periods of USD -21.05 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -109.45 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit

Lowest at USD -38 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -141.19 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -2.39

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Cash and Eqv

Lowest at USD 557.7 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 4.25 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 5.71% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales